{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:36:44Z","timestamp":1758044204815,"version":"3.44.0"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Medication adherence is a critical component in the treatment of psychiatric conditions such as obsessive-compulsive disorder (OCD). Poor adherence is associated with an increased risk of relapse, subsequent (re)hospitalization, and prolonged remission, which ultimately leads to a worse prognosis. This study aimed to assess medication adherence over time in individuals with OCD, identify predictors, and gather patient-reported strategies to maintain adherence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study surveyed <jats:italic>N<\/jats:italic> = 100 patients recruited in the outpatient department of a university medical center in Leipzig, Germany, between January 2019 and January 2020 (Ethics Committee approval number: 332\/18-ek; date of approval: 25 September 2018). Medication adherence was assessed using indirect (i.e., Drug Attitude Inventory, Medication Adherence Rating Scale) and direct methods (i.e., therapeutic drug monitoring via serum drug concentration). Additionally, the participants reported strategies they found helpful for maintaining adherence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The participants exhibited mild impairments in various aspects of functioning despite relatively functional daily lives. Most were prescribed selective serotonin reuptake inhibitors (SSRIs), with a subset receiving combination therapy for treatment-resistant cases. Medication adherence was classified into three categories: 24.4% of the participants were good adherers, 62.2% were partially adherent, and 13.4% were non-adherent. Therapeutic drug monitoring (TDM) indicated that 84.6% of the participants had drug levels within the therapeutic range. Concerns about side effects and doubts regarding the efficacy of the medication were commonly reported, which might contribute to suboptimal adherence. However, no significant associations were found between adherence and sociodemographic or clinical variables, which suggested the need for a more comprehensive approach considering psychosocial factors. Behavioral strategies for maintaining adherence (e.g., incorporating medication into daily routines) were preferred and rated as helpful, while invasive monitoring methods were largely rejected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study highlights the importance of a multifaceted approach to improving medication adherence in individuals with OCD. While SSRIs remain the primary pharmacological treatment, a significant portion of patients still struggle with adherence. Although TDM provides valuable insights into drug levels, it may not fully capture adherence behavior due to metabolic and behavioral variability. Addressing patient concerns about side effects and medication efficacy, alongside implementing behavioral strategies that integrate medication into daily routines, may improve adherence and enhance treatment outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2025.1642622","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T10:45:32Z","timestamp":1757673932000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Medication adherence in obsessive-compulsive disorders and evaluation of effective adherence support strategies"],"prefix":"10.3389","volume":"16","author":[{"given":"Sophia","family":"P\u00f6ppel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sina","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klara","family":"Bednasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Kohls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Rummel-Kluge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"B1","volume-title":"Adherence to long-therm therapies: Evidence for action","year":"2003"},{"key":"B2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S29549","article-title":"Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions","volume":"7","author":"Hugtenburg","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"B4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0738-3991(78)80033-0","article-title":"Patient compliance with antihypertensive regimens","volume":"1","author":"Sackett","year":"1978","journal-title":"Patient Couns Health Educ"},{"key":"B5","doi-asserted-by":"publisher","first-page":"CD000011","DOI":"10.1002\/14651858.CD000011","article-title":"Interventions for helping patients to follow prescriptions for medications","author":"Haynes","year":"2002","journal-title":"Cochrane Database Systematic Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"CD000011","DOI":"10.1002\/14651858.CD000011.pub2","article-title":"Interventions to enhance medication adherence","author":"Haynes","year":"2005","journal-title":"Cochrane Database Systematic Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2002.1r084.x","article-title":"Treatment non-adherence in affective disorders","volume":"105","author":"Lingam","year":"2002","journal-title":"Acta Psychiatr Scand"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.1.101","article-title":"Continuity of antidepressant treatment for adults with depression in the United States","volume":"163","author":"Olfson","year":"2006","journal-title":"AJP"},{"key":"B9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.psychres.2014.11.002","article-title":"A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders","volume":"225","author":"Sendt","year":"2015","journal-title":"Psychiatry Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"B11","volume-title":"Internationale Klassifikation psychischer St\u00f6rungen: ICD-10 Kapitel V (F), klinisch-diagnostische Leitlinien. 10., \u00fcberarb. Aufl. unter Ber\u00fccksichtigung der \u00c4nderungen entsprechend ICD-10-GM 2015","author":"Dilling","year":"2015"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2014.06.004","article-title":"Obsessive-compulsive disorder","volume":"37","author":"Goodman","year":"2014","journal-title":"Psychiatr Clin North Am"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0261169","article-title":"Long durations from symptom onset to diagnosis and from diagnosis to treatment in obsessive-compulsive disorder: A retrospective self-report study","volume":"16","author":"Ziegler","year":"2021","journal-title":"PloS One"},{"key":"B14","unstructured":"S3-Leitlinie Zwangsst\u00f6rungen: Erste Revision im Juni 2022\n          \n          \n          \n          2022"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04269","article-title":"Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients","volume":"70","author":"Vulink","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyv047","article-title":"Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials","volume":"18","author":"Dold","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"B17","volume-title":"Diagnostisches und statistisches Manual psychischer St\u00f6rungen: DSM-IV; \u00fcbersetzt nach der vierten Auflage des Diagnostic and statistical manual of mental disorders der American Psychiatric Association. 3., unver\u00e4nd","author":"Sa\u00df","year":"2001"},{"key":"B18","volume-title":"Diagnostic and statistical manual of mental disorders: DSM-5","year":"2013"},{"key":"B19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1055\/s-2007-970894","article-title":"Das Zwangsinventar OCI-R - die deutsche Version des Obsessive-Compulsive Inventory-Revised - Ein kurzes Selbstbeurteilungsinstrument zur mehrdimensionalen Messung von Zwangssymptomen","volume":"57","author":"G\u00f6nner","year":"2007","journal-title":"Psychother Psychosom Med Psychol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.janxdis.2006.05.006","article-title":"The OCI-R: validation of the subscales in a clinical sample","volume":"21","author":"Huppert","year":"2007","journal-title":"J Anxiety Disord"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291700050182","article-title":"A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity","volume":"13","author":"Hogan","year":"1983","journal-title":"Psychol Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(99)00130-9","article-title":"Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses","volume":"42","author":"Thompson","year":"2000","journal-title":"Schizophr Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med Care"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.5530\/ctbp.2020.4s.24","article-title":"Revisiting the intractable barriers affecting medication adherence among outpatients with schizophrenia","volume":"14","author":"Julaeha","year":"2020","journal-title":"CTBP"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"B26","article-title":"t Test, Paired Samples","volume-title":"Encyclopedia of research design","author":"Stone","year":"2010"},{"key":"B27","volume-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1988"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1037\/1040-3590.14.4.485","article-title":"The Obsessive-Compulsive Inventory: Development and validation of a short version","volume":"14","author":"Foa","year":"2002","journal-title":"psychol Assess"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4103\/psychiatry.IndianJPsychiatry_519_18","article-title":"Antipsychotic augmentation in the treatment of obsessive-compulsive disorder","volume":"61","author":"Thamby","year":"2019","journal-title":"Indian J Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14656566.2018.1540590","article-title":"A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder","volume":"20","author":"Brakoulias","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2009.04.003","article-title":"Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice","volume":"19","author":"Goodwin","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001823","article-title":"A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder","volume":"11","author":"Bloch","year":"2006","journal-title":"Mol Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2024.575","article-title":"Treatment adherence rates across different psychiatric disorders and settings: findings from a large patient cohort","volume":"67","author":"Girone","year":"2024","journal-title":"Int Clin Psychopharmacol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.12809","article-title":"Non-adherence to psychotropic medication assessed by plasma level in newly admitted psychiatric patients: Prevalence before acute admission","volume":"73","author":"Geretsegger","year":"2019","journal-title":"Psychiatry Clin Neurosci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2013.08.026","article-title":"Treatment adherence in bipolar I and schizoaffective disorder, bipolar type","volume":"151","author":"Murru","year":"2013","journal-title":"J Affect Disord"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e100180","DOI":"10.1136\/gpsych-2019-100180","article-title":"Cross-sectional study of internalised stigma and medication adherence in patients with obsessive compulsive disorder","volume":"33","author":"Ansari","year":"2020","journal-title":"Gen Psychiatr"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.4324\/9781315806488","volume-title":"Prospective Memory","author":"Brandimonte","year":"2014"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.826138","article-title":"Is therapeutic drug monitoring relevant for antidepressant drug therapy? Implications from a systematic review and meta-analysis with focus on moderating factors","volume":"13","author":"Funk","year":"2022","journal-title":"Front Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.3390\/pharmaceutics14122674","article-title":"Current status of therapeutic drug monitoring in mental health treatment: A review","volume":"14","author":"Pennazio","year":"2022","journal-title":"Pharmaceutics"},{"key":"B40","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3390\/ph17050642","article-title":"Therapeutic drug monitoring in psychiatry: enhancing treatment precision and patient outcomes","volume":"17","author":"Biso","year":"2024","journal-title":"Pharm (Basel)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2174\/157340009788971137","article-title":"A review of modern antidepressants effects on neurocognitive function","volume":"5","author":"Biringer","year":"2009","journal-title":"CPSR"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2006.01.018","article-title":"Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy","volume":"91","author":"Gallassi","year":"2006","journal-title":"J Affect Disord"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2783","article-title":"Change in cognitive functioning in depressed older adults following treatment with sertraline or nortriptyline","volume":"27","author":"Culang-Reinlieb","year":"2012","journal-title":"Int J Geriatr Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32825ea312","article-title":"Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder","volume":"22","author":"Fineberg","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"CD001765","DOI":"10.1002\/14651858.CD001765.pub3","article-title":"Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)","volume":"2008","author":"Soomro","year":"2008","journal-title":"Cochrane Database Systematic Rev"},{"key":"B46","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4103\/ipj.ipj_133_21","article-title":"Effect of sertraline and fluvoxamine on quality of life in patients with obsessive-compulsive disorder: A 12-week interventional study","volume":"31","author":"Brar","year":"2022","journal-title":"Ind Psychiatry J"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2005.04.002","article-title":"Quality of life in obsessive-compulsive disorder before and after treatment","volume":"46","author":"Moritz","year":"2005","journal-title":"Compr Psychiatry"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2013.09.001","article-title":"Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS(\u00ae)) in the Swedish COAST-study","volume":"23","author":"Brain","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jad.2010.05.021","article-title":"Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample","volume":"127","author":"Guti\u00e9rrez-Rojas","year":"2010","journal-title":"J Affect Disord"},{"key":"B50","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1586\/ern.09.62","article-title":"Improving adherence in mood disorders: the struggle against relapse, recurrence and suicide risk","volume":"9","author":"Pompili","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1177\/2045125312474019","article-title":"Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review","volume":"3","author":"Higashi","year":"2013","journal-title":"Ther Adv Psychopharmacol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.schbul.a006898","article-title":"A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years","volume":"27","author":"Linden","year":"2001","journal-title":"Schizophr Bull"},{"key":"B53","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40345-019-0154-z","article-title":"Trajectories of adherence to mood stabilizers in patients with bipolar disorder","volume":"7","author":"Bauer","year":"2019","journal-title":"Int J Bipolar Disord"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2013.01.036","article-title":"Determinants of adherence to treatment in bipolar disorder: a comprehensive review","volume":"149","author":"Leclerc","year":"2013","journal-title":"J Affect Disord"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2008.09.007","article-title":"Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variables","volume":"107","author":"Acosta","year":"2009","journal-title":"Schizophr Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.2196\/53513","article-title":"Medication management strategies to support medication adherence: interview study with older adults","volume":"13","author":"Gualtieri","year":"2024","journal-title":"Interact J Med Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1037\/0033-295X.114.4.843","article-title":"A new look at habits and the habit-goal interface","volume":"114","author":"Wood","year":"2007","journal-title":"Psychol Rev"},{"key":"B58","article-title":"Prospective memory and medication adherence","volume-title":"Prospective Memory","author":"Park","year":"2014"},{"key":"B59","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11886-017-0918-y","article-title":"Improving medication adherence in coronary heart disease","volume":"19","author":"Zullig","year":"2017","journal-title":"Curr Cardiol Rep"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.4.2.175","article-title":"The influence of circadian rhythms on the kinetics of drugs in humans","volume":"4","author":"Baraldo","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1177\/152692480901900211","article-title":"Medication adherence in successful kidney transplant recipients","volume":"19","author":"Ruppar","year":"2009","journal-title":"Prog Transplant"},{"key":"B62","doi-asserted-by":"crossref","DOI":"10.1145\/2556288.2557079","article-title":"Don\u2019t forget your pill","volume-title":"Proceedings of the SIGCHI Conference on Human Factors in Computing Systems","author":"Stawarz","year":"2014"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.3951","article-title":"Impact of mHealth chronic disease management on treatment adherence and patient outcomes: a systematic review","volume":"17","author":"Hamine","year":"2015","journal-title":"J Med Internet Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1037\/h0091854","article-title":"Research on relationship-centered care and healthcare outcomes from the Rochester biopsychosocial program: A self-determination theory integration","volume":"18","author":"Williams","year":"2000","journal-title":"Families Systems Health"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1642622\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T10:45:35Z","timestamp":1757673935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1642622\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":64,"alternative-id":["10.3389\/fpsyt.2025.1642622"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1642622","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"article-number":"1642622"}}